 | Up a level |
2021
Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S. and Heinemann, V (2021). Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur. J. Cancer, 146. S. 95 - 107. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
2018
Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R. J. C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C. B., Kruger, S., Boeck, S. and Heinemann, V. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 29. S. 243 - 244. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2015
Porschen, R., Buck, A., Fischbach, W., Gockel, I., Goerling, U., Grenacher, L., Hollerbach, S., Hoelscher, A., Koerber, J., Messmann, H., Meyer, H. J., Miehlke, S., Moehler, M., Noethlings, U., Pech, U., Schmidberger, H., Schmidt, M., Stahl, M., Stuschke, M., Thuss-Patience, P., Trojan, J., Vanhoefer, U., Weimann, A., Wenz, F. and Wullstein, C. (2015). S3-Guidelines Diagnosis and Treatment of Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus (Long Version 1.0-September 2015, AWMF-Register Number: 021/023OL). Z. Gastroent., 53 (11). S. 1288 - 1348. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-7803